Azitra, Inc. (AZTR)
| Market Cap | 7.59M +102.6% |
| Revenue (ttm) | n/a |
| Net Income | -12.27M |
| EPS | -0.98 |
| Shares Out | 60.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 602,349 |
| Open | 0.1268 |
| Previous Close | 0.1250 |
| Day's Range | 0.1234 - 0.1291 |
| 52-Week Range | 0.1000 - 1.4000 |
| Beta | -1.18 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About AZTR
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Ph... [Read more]
Financial Performance
Financial StatementsNews
Azitra reports Q2 EPS (17c) vs. ($1.18) last year
“The second quarter has marked an exciting evolution for Azitra (AZTR) with the first data from our ATR-COSF program, which provided validation of our strategy to leverage our microbial genetic…
Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
BRANFORD, Conn., Aug. 12, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for...
Azitra Quarterly report: Q2 2026
Azitra has published its Q2 2026 quarterly earnings report on August 12, 2026.
Azitra Earnings release: Q2 2026
Azitra released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Meet Azitra: Fly Exclusive with CEO Francisco Salva
In an exclusive interview, Azitra (AZTR) CEO Francisco Salva spoke with The Fly about the company’s expanding strategy, the science behind its recombinant protein programs, the commercial potential of...
Azitra building multi market microbial engineering platform, CEO says
14:00 EDT Azitra (AZTR) building multi market microbial engineering platform, CEO says
Azitra says Phase 1/2 ATR 04 trial remains on track for topline data this year
14:00 EDT Azitra (AZTR) says Phase 1/2 ATR 04 trial remains on track for topline data this year
CEO says breadth of Azitra’s platform opens multiple attractive markets
14:00 EDT CEO says breadth of Azitra’s (AZTR) platform opens multiple attractive markets
Azitra announces results from two ex vivo human skin tissue studies
Azitra (AZTR) announced results from two separate ex vivo human skin tissue studies. The studies evaluated the distribution and anti-wrinkle activity of Azitra’s filaggrin domain containing supernatan...
Azitra, Inc. Announces Breakthough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity
ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin ("rHDfilaggrin"). This S. epidermis derived supernatant is in development as a hig...
Azitra Slides: Corporate presentation
Azitra has posted slides in relation to its latest quarterly earnings report, which was published on July 10, 2026.
Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
BRANFORD, Conn., June 17, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for...
Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
BRANFORD, Conn., June 4, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today...
Azitra Proxy statement: Proxy filing
Azitra filed a proxy statement on June 4, 2026, providing details for shareholder voting and corporate governance matters.
Azitra Announces Intention to Adjourn Annual Meeting and Reconvene Annual Meeting
BRANFORD, Conn., May 27, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today...
Azitra Proxy statement: Proxy filing
Azitra filed a proxy statement on May 27, 2026, providing details for shareholder voting and corporate governance matters.
Azitra files to sell 255.7M shares of common stock for holders
16:58 EDT Azitra (AZTR) files to sell 255.7M shares of common stock for holders
Azitra Registration statement: Registration filing
Azitra filed a registration statement on May 21, 2026, providing details about a securities offering with the SEC.
Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates
BRANFORD, Conn., May 13, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for ...
Azitra Quarterly report: Q1 2026
Azitra has published its Q1 2026 quarterly earnings report on May 13, 2026.
Azitra Earnings release: Q1 2026
Azitra released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Azitra Proxy statement: Proxy filing
Azitra filed a proxy statement on May 8, 2026, providing details for shareholder voting and corporate governance matters.
Azitra granted new U.S. patent protecting ATR-12 program
Azitra (AZTR) announced the issuance of a new U.S. patent protecting ATR-12, the company’s lead product candidate. Azitra is advancing ATR-12 in a Phase 1b clinical trial as a treatment…
Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program
Patent offers broad protections for ATR-12, an engineered strain of S. epidermidis that expresses a fragment of human LEKTI protein ATR-12 is currently the subject of a Phase 1b trial for the treatmen...
Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris
Preclinical data demonstrate ATR-01 delivers functional filaggrin, restoring skin barrier integrity and supporting advancement toward first-in-human studies BRANFORD, Conn., April 28, 2026 /PRNewswire...